Despite the pause, the company clarified that the suspension does not impact commercial activity outside the US.

Despite advances in the treatment of myocardial infarction (MI), the incidence of cardiogenic shock has remained at 7% to 10% during the last 25 years. Hospital mortality was about 90% in the ...

The year held a number of surprises, including a few negative studies, as well as a big win for Impella in DanGer Shock.

including those suffering from acute heart failure and cardiogenic shock. The agency expanded its previous premarket approvals for the catheter-based Impella 5.5 and CP pumps developed by Abiomed ...

CS may present as an early complication following ST elevation and MI. In the SHOCK trial, the median time from MI to shock onset was 5.0 hours (25th to 75th percentile, 2.2-12.0 hours ...

Impella 5.5 and Impella CP are the first left-sided, minimally invasive temporary mechanical circulatory support options for pediatric patients with symptomatic ADHF and cardiogenic shock DANVERS ...

Similarly, the Impella 5.5 with SmartAssist System is approved for short-term use of up to 14 days for paediatric patients weighing at least 30kg, also addressing cardiogenic shock under similar ...

Please provide your email address to receive an email when new articles are posted on . Two heart pump systems were approved for the treatment of acute decompensated HF and cardiogenic shock in ...